<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02646904</url>
  </required_header>
  <id_info>
    <org_study_id>9-2015</org_study_id>
    <nct_id>NCT02646904</nct_id>
  </id_info>
  <brief_title>Nebulized Beclometasone Dipropionate Improves Nasal Patency in Children With Allergic Rhinitis</brief_title>
  <official_title>Nebulized Beclometasone Dipropionate Improves Nasal Patency in Children With Allergic Rhinitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stefania La Grutta, MD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Istituto di Biomedicina e Immunologia Molecolare Alberto Monroy</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to examine in children with persistent AR the effect of the
      topically applied beclomethasone in comparison with cetirizine on nasal patency evaluated by
      acoustic rhinometry and subjective nasal symptoms.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 2016</start_date>
  <completion_date type="Actual">July 2017</completion_date>
  <primary_completion_date type="Actual">June 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Nasal patency evaluated by acoustic rhinometry.</measure>
    <time_frame>21 days</time_frame>
    <description>The main objective is to assess the increase of nasal patency in children aged 6-16 with perennial allergic rhinitis (PAR), treated with Beclometasone nasal spray 100 µg/die for 21 days.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy of Beclometasone nasal spray on subjective nasal symptoms</measure>
    <time_frame>21 days</time_frame>
    <description>The secondary objective is to measure the impact of Beclometasone nasal spray 100 µg on subjective nasal symptoms, in children aged 6-16 with perennial allergic rhinitis (PAR), assessed by T4SS Questionnaire(Total 4 Symptoms Score).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">68</enrollment>
  <condition>Allergic Rhinitis</condition>
  <arm_group>
    <arm_group_label>Beclometasone Dipropionate (BDP)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Standard dose (400 µg/daily as 100 µg 1 spray nos bid) of Nasal Beclomethasone Dipropionate for 21 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CERCHIO 10 mg/ml OS</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>For Children &lt; 12 years old 10 drops die (5 mg die) for 21 days. For Children &gt; 12 years old 20 drops die (10 mg die) for 21 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nasal Beclomethasone Dipropionate</intervention_name>
    <description>Standard dose (400 µg/daily as 100 µg 1 spray nos bid) of nebulized Beclomethasone Dipropionate nasal spray for 21 days.</description>
    <arm_group_label>Beclometasone Dipropionate (BDP)</arm_group_label>
    <other_name>NBDP</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CERCHIO 10 mg/ml OS</intervention_name>
    <description>For Children &lt; 12 years old 10 drops die (5 mg die) for 21 days. For Children &gt; 12 years old 20 drops die (10 mg die) for 21 days.</description>
    <arm_group_label>CERCHIO 10 mg/ml OS</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  children 6-16 years of age with a history of AR in the previous year

          -  T5SS: ≥5 in the last week before enrollment

        Exclusion Criteria:

          -  asthma symptoms

          -  acute upper respiratory infections

          -  anatomic nasal defects (ie, septum deviation), or nasal polyps

          -  use in the past 4 weeks of nasal or oral corticosteroids, nasal or oral decongestants,
             antihistamines.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>16 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Institute of Biomedicine and Molecular Immunology (IBIM), National Research Council</name>
      <address>
        <city>Palermo</city>
        <state>Sicily</state>
        <zip>90146</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute of Biomedicine and Molecular Immunology, IBIM</name>
      <address>
        <city>Palermo</city>
        <zip>90146</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 18, 2015</study_first_submitted>
  <study_first_submitted_qc>January 5, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 6, 2016</study_first_posted>
  <last_update_submitted>November 17, 2017</last_update_submitted>
  <last_update_submitted_qc>November 17, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 20, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Istituto di Biomedicina e Immunologia Molecolare Alberto Monroy</investigator_affiliation>
    <investigator_full_name>Stefania La Grutta, MD</investigator_full_name>
    <investigator_title>MD, Senior Researcher, Coordinator of Pediatric Allergy and Asthma Research Group. Institute of Biomedicine and Molecular Immunology, IBIM, National Research Council of Palermo, Italy.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rhinitis</mesh_term>
    <mesh_term>Rhinitis, Allergic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Beclomethasone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>The IPD collected will be available on February 2017.
The following participant data will be shared:
Nasal patency
Nasal symptom score
Demographic characteristics
All IPD will be obtained from statistical analysis on the dedicated database in which all data are stored.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

